BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The present trial will be performed to determine the MTD and to evaluate the efficacy of BI
2536 in the treatment of elderly patients with relapsed or refractory AML. Different
schedules will be compared to identify the better dosing schedule for the further development
programme of BI 2536. Dose escalation starting with the maximum tolerated dose previously
determined in patients with advanced solid cancers will be performed to determine the maximum
tolerated dose for AML patients.